23ANDME HOLDING CO -CLASS A (ME)
US90138Q1085 - Common Stock
2.08 +0.04 (+1.96%)
After market: 2.07 -0.01 (-0.48%)
23andMe GAAP EPS of -$0.14 beats by $0.04, revenue of $92.4M beats by $4M (NASDAQ:ME)
23andMe press release (NASDAQ:ME): Q4 GAAP EPS of -$0.14 beats by $0.04.Revenue of $92.4M (-8.1% Y/Y) beats by $4M.
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN...
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both.
3 Key Biotech Trends for 2023 And Beyond
New opportunities are becoming apparent, but so are fresh risks in the biotech field.
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their...
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe+ members can now gain insights on the chronic autoimmune condition
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe+ members can now gain insights on the chronic autoimmune condition...
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with...
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell...
23andMe Publishes Inaugural Environmental, Social and Governance Report
/PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access,...
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers...
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented...
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
They've been using machine learning for years, and now they might do even more.
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could...
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
There's nothing better than getting a bargain that'll pay off for years.
Asia’s Richest Man Mukesh Ambani to Foray Into Genome Testing with $145 Kit
Mukesh Ambani's Reliance is seeking to disrupt DNA testing with $145 genome sequencing kits — undercutting rivals charging $1,000
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Both are likely to double quite soon, and they aren't even that risky.
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610
23andMe to Present at Upcoming Investor Conferences
23andMe to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...
This Genetics Stock Could Have Massive Long-Term Potential
This healthcare company isn't without risk but is doing a good job executing on its vision.